Analysis of Asian Markets
9:45 a.m. to 10:45 a.m.
|
|
)
)
)
)
)
Gail Garland
Gail Garland works as a Marketing and Channel Management Consultant at Axela Inc. She has worked with international companies in areas such as marketing and brand strategy, sales, general management and business development. She has held progressively senior roles with industry leaders including Alcon and Johnson & Johnson. From 2003 to 2008 she was Vice President, Business Development at Bioniche Life Sciences Inc. where she led teams with worldwide responsibilities for product commercialization and partnering activities. Gail holds a Bachelor of Science degree as well as, an MBA from Rotman School of Management, University of Toronto (Dean’s List). She is currently working towards attaining her Chartered Director Designation in Corporate Governance from McGill University and The Conference Board of Canada. In September of 2008 she led the team that organized the successful TBI Mix and Match event held at Astra Zeneca. She and Dr. Adi Treasurywala have recently launched the TBI Mentoring Program. She serves on the TBI Membership Committee. She will co-chair the Strategy Sessions for today’s conference together with Matt Buist. In the past, Gail has served as a Board Member of the Alumni Association Rotman School of Management and Co-Chair of the Rotman Vision Fund. She was awarded the University of Toronto Arbor Award for Outstanding Volunteer Service in 2003. Gail visited China as part of a Federal Trade Mission in 2005.
Sarah E. Frew
Sarah E. Frew is a Research Associate at the McLaughlin-Rotman Centre for Global Health, Program on Ethics and Commercialization, at the University Health Network and University of Toronto. Her research focuses on the homegrown health biotech sectors in emerging markets and developing countries, with a particular focus on the partnerships and internal capabilities of domestic firms to address local health needs. Dr. Frew has personally visited over 60 of the leading innovative health biotech companies in India, China, Brazil and South Africa, and conducted in-depth interviews with senior management. Through this work she has developed a keen understanding of (1) the capabilities of these nascent sectors along the product development value chain and (2) the strategies utilized by the firms to survive and grow amid a myriad of challenges related to operating in a developing world context. Dr. Frew believes that this research can lay the groundwork for a more sustainable approach to global health development, in which homegrown private industry can empower citizens to tackle both local disease burden and poverty.
Dr. Frew’s work has been published in prestigious peer-reviewed journals, including Nature Biotechnology and Health Affairs, and she has conducted interviews with numerous international media sources, such as the International Herald Tribune, CNNMoney.com, Forbes, and BBC Radio World Service, to bring this work to the broader public. Multiple audiences have shown their interest in this work, including: biotechnology firms seeking partnerships, venture capitalists seeking investment opportunities, foundations interested in global health solutions, and developing world governments seeking ideas about successful innovation strategies.
Dr. Frew graduated with University Honors from Carnegie Mellon University and received a PhD in cancer cell biology from the Massachusetts Institute of Technology. She has taken courses on international science and technology policy at the Kennedy School of government (Harvard University) and on entrepreneurship at the Sloan School of Management (MIT). In 2007, she received executive management certificates from the Rotman School of Management (University of Toronto) and Harvard Business School.
Paul Stinson
Paul Stinson is the driving force behind CAPRA International. As President of CAPRA International, he brings 20 years of extensive experience in the global biopharmaceutical industry. His experience has led him to senior executive positions in biopharmaceutical companies in over 4 continents, including Asia, North America, Europe, and Africa.
Amongst his diverse set of skills as a senior executive, Paul has the ability to turn around loss-making operations and managing change, managing mid-sized, multi-divisional organisations, strategic planning, fostering collaboration, and mentoring. His working knowledge of 4 different languages has allowed him to develop a keen sense for building partnerships and the difficult task of bridging different cultures.
More recently, he has served as Executive Director of BC BioTech, and Director General in the Human Proteome Organisation (HUPO). In those roles, he has frequently traveled to Asia for business development and to develop partnering opportunities.. In addition, he has participated in a number of Canada Government-led initiatives to other countries.
He received his Bachelor's degree from the University of Western Ontario, and his Masters in Business Administration degree from IMD (International Institute of Management Development) in Lausanne, Switzerland.
Ron Choudhury
Ron Choudhury is an associate and member of the firm's Tax Group and Estates and Trusts Litigation Team. Prior to joining A&B, Ron was an associate in the tax group of another large Toronto law firm.
Practice
Ron's practice focuses on corporate and international tax, including tax aspects of reorganizations, takeovers, divestitures, acquisitions, inbound and outbound financing transactions, asset securitization, public offerings and executive compensation. He has acted for multinational corporations and owner-managers on transactional matters and advised on major domestic and cross-border acquisition and financing transactions. Ron has also advocated before the Canada Revenue Agency and the Ontario Ministry of Finance.
Ron is also involved in the firm's India initiative and acts on behalf of Indian companies establishing in Canada as well as Canadian companies considering India as an investment destination. Ron has experience in both inbound and outbound financing, investment and corporate transactions involving Canada and India.
Recognitions and Awards
Awarded the International Bar Association Taxation Section Scholarship, 2008.
Recognized by the Indo-Canada Chamber of Commerce as 2006 Member of the Year. The award was presented to the Young Professionals' Committee chaired by Ron.
Teaching Engagement: Guest instructor, University of Western Ontario Law, Tax Planning Course
Memberships: Ontario Bar Association, Taxation Law Section Executive
Canadian Tax Foundation
South Asian Bar Association of Toronto, President
North American South Asian Bar Association, Director
International Fiscal Association
EducationLL.M., Taxation, New York University, 2003
LL.B., Osgoode Hall Law School, 2001
B.A., University of Toronto, 1998
Hadi Salah
Hadi Salah is an Industry Analyst with the Frost & Sullivan's Technical Insights division. His main focus at Frost & Sullivan is to track emerging and disruptive technologies in healthcare, biotechnology, nanotechnology, and cleantech.
Since joining Frost & Sullivan, Hadi has led various consulting projects for clients of all sizes, from start-up to Fortune 500 companies. He has evaluated and commented on technology developments, devised growth strategies, analyzed markets and generated forecast reports. Along with consulting, Hadi dedicates resources to business development and Frost & Sullivan’s Toronto Office social committee.
Prior to Frost & Sullivan, Hadi conducted scientific research at the Hospital for Sick Children (Toronto, Canada) in the fields of cell biology, immunity, and cystic fibrosis. Besides scientific research, he conducted market due diligence, technology evaluation, and commercialization at the Innovations Group, the University Health Network, and Dundee Securities Inc. He holds a Bachelor's Degree (Biology and Biotechnology) from the University of Ottawa and a Master’s degree in Laboratory Medicine & Pathobiology from the University of Toronto..
